“ANAVEX 2-73 was recognized by the independent publication Alzheimer's Weekly as "The number one most promising drug in Alzheimer's Disease" after their analysis of more than 100 trials that treat dementias and following the review of more than 10,000 articles.”
Doing their own due dilligence before making any investments is on potential investors to weigh their own risk reward senerio. I find the rewards of investing here to far outweigh the risk at this share price. But then again, that's me. I'm totally in now and don't lose any sleep over this investment. I like the fact that their strategy is to attack this disease upstream and to combine with another drug to repair some of the damage that has already been done.
H2 is less than a month away. Investigational New Drug application to be filed in the second half of the year.
This explains it a bit better:
Anavex to Present Initial Clinical Data From the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer’s Association International Conference (AAIC)
June 30, 2015 07:47
My thought is that it will be you running away with your tail tucked. I'm quite confident that Pfizer or another deep pocketed pharaceutical company will step in to be part of what AVXL has in its pipeline. Stay tuned.
Leadership has changed since 2006:
Our Pipeline is quite robust:
And here’s a list of potential indications for our future clinical trials:
Here’s a few words from our CEO:
New York — January 12, 2015
Anavex Doses First Alzheimer’s Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS
The first part (PART A) is a simple randomized, open-label, two-period, cross-over, adaptive trial lasting up to 36 days. The primary objective of Part A is to evaluate the maximum tolerated dose of ANAVEX 2-73 in these patients.
The second part (PART B) is an open-label extension in Phase 2a adaptive clinical trial of ANAVEX 2-73 and ANAVEX PLUS. At least 32 mild to moderate Alzheimer’s patients will be enrolled and they will be able to receive the study drug for up to 26 weeks to establish a longer drug effect to evaluate dose response, bioavailability, cognitive efficacy and the relationship of ANAVEX 2-73 as an add-on therapy to donepezil, the current standard of care.
Agreed 100%. Wait until AVXL reaches $20.00 then we'll talk. Don't forget the Epilepsy indication and several others.
This stock is a Buy and Hold now. A simple math equasion: the less shares available for sale, the higher the price. I think it's called supply and demand.
"The MJFF grant is expected to fully fund a preclinical study on the effect of ANAVEX 2-73 in a Parkinson’s disease animal model, which seeks to provide a solid dataset that will justify moving forward to clinical development in Parkinson’s. "
Nice try anny
Hello Peter. I plan to hold for at least a year so my capital gains tax will be around 15% instead of close to 30%. In addition to that, I believe in the science and realize the sky is the limit on this investment. This stock is way underpriced right now. It is hard to put a value on it because there are a lot of drugs in its pipeline. These are drugs that could potentially be worth billions of dollars. Our management team is top notch. The folks we have on board wouldn't be there if they didn't believe in the science. Congratulations on finding this gem in your early investing career
Either folks believe in the science or they don't. Seems some don't. Maybe they shouldn't invest here. I'm in at 27 cents and have no intention of selling anytime soon. So, I guess you could say I believe in the science. All indications look like this probably stops and possibly reverses Alzheimer's Disease. There's always a risk but I think McFarlane's enthusiasm is coming from the results he sees and not a p&d. Just my opinion.